The Association of Illness Severity, Self-Reported Cognitive Impairment, and Perceived Illness Management with Depression and Anxiety in a Multiple Sclerosis Clinic Population

Lester, Kristin; Stepleman, Lara M.; Hughes, Mary D.

doi:10.1007/s10865-007-9095-6

Cited by 73 publications

(64 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…12,14,15,22 In contrast, reports of cognitive concerns on the PDQ were highly correlated with concomitant reports of depression, anxiety, fatigue, and self-efficacy, in line with existing literature. 15,19,21 Among these variables, reports on the PDQ were most highly correlated with vegetative symptoms of depression (r = 0.60 to 0.66) addition, each index of the PDQ (ie, Attention, Memory, and Planning) maintained significant associations with each self-report factor. See Table 4 for the correlations with the specific breakdown of all the subscales of the PDQ.…”

Section: Resultsmentioning

confidence: 95%

“…They suggested that further attention to the role of self-efficacy was warranted as both a direct and mediating effect on perceived functioning. 21 The aim of the present study was, thus, to examine the relationship between subjective cognitive concerns on the PDQ and objective neuropsychological performance while taking into account the possible confounding factors of depression, anxiety, fatigue, and selfefficacy. We hypothesized that the correlation between subjective cognitive concerns and objective performance on a neuropsychological test battery would be inconsistent, at best.…”

Section: Methodsmentioning

confidence: 99%

“…As with fatigue, there is growing evidence of a relationship between self-reported cognitive symptoms and anxiety. Lester et al 21 found that anxiety symptoms contributed to one's perceived cognitive impairments, in conjunction with depression. Furthermore, Akbar et al 22 found depression, anxiety, and personality to be associated with cognitive concerns as measured by the MSNQ and not reflective of objective cognitive impairment on the BRNB.…”

mentioning

confidence: 99%

See 2 more Smart Citations

The Perceived Deficits Questionnaire

Strober¹,

Binder²,

Nikelshpur³

et al. 2016

International Journal of MS Care

View full text Add to dashboard Cite

Background:Cognitive dysfunction affects approximately 43% to 70% of individuals with multiple sclerosis (MS) and is an important determinant of several functional outcomes in MS and quality of life. Brief neuropsychological test batteries have been developed specifically for use in MS and are widely used to aid clinicians in assessing levels of cognitive impairment in MS. Neuropsychologists and neurologists also frequently use briefer screening measures, such as the Perceived Deficits Questionnaire (PDQ), to assist in determining whether a more extensive neuropsychological evaluation is warranted. However, despite the ease of such measures, the relationship between self-report and objective cognitive impairment has been inconsistent, at best. Moreover, factors such as depression, fatigue, anxiety, and personality have been found to be more related to reports of cognitive difficulties. The purpose of the present study was to clarify the relationship between subjective cognitive concerns and objective cognitive impairment while accounting for related symptoms.

show abstract

Section: Resultsmentioning

confidence: 95%

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

The Perceived Deficits Questionnaire

Strober¹,

Binder²,

Nikelshpur³

et al. 2016

International Journal of MS Care

View full text Add to dashboard Cite

show abstract

“…It has been well documented that depression in patients with MS is related to a poorer quality of life, diminished positive outlook, and, most importantly, reduced adherence to treatment. [24][25][26][27] Therefore, a history of depression has led to many prescribers avoiding IFNβ therapy for their patients, based on findings in the pivotal interferon studies that suggested a possible increase in depressive symptoms after starting IFNβ therapy. 1,11 This study as well as other comparison studies have not supported those earlier findings.…”

Section: Use Of Concomitant Antidepressant Medicationmentioning

confidence: 99%

Relationship Between Disease-Modifying Therapy and Depression in Multiple Sclerosis

Kirzinger¹,

Jones²,

Siegwald³

2013

International Journal of MS Care

View full text Add to dashboard Cite

Many prescribers of disease-modifying therapies (DMTs) for multiple sclerosis (MS) believe that interferon beta (IFNβ) is more likely than glatiramer acetate (GA) to increase depression during the course of MS treatment. Therefore, newly diagnosed patients with a history of depression are often placed on GA therapy from the onset of MS treatment. The aim of this study was to examine the relationship between DMT type and depression among patients with relapsing-remitting MS (RRMS). Patients with RRMS who were examined from 2000 to 2007 and who remained on a single course of therapy (either an IFNβ or GA) were included in a retrospective review of medical records. Patients were asked to complete the Beck Depression Inventory (BDI) at treatment initiation and every 6 months thereafter for up to 4 years. Only patients who had completed a BDI within 6 weeks of starting their DMT were included in the analysis. No significant differences in mean change in BDI score were observed from baseline to 48 months between the IFNβ and GA subgroups. Additionally, no significant differences in mean BDI score change were observed between antidepressant-treated and non–antidepressant-treated patients within the IFNβ or GA subgroup. Neither IFNβ nor GA therapy appears to exacerbate depressive symptoms in patients with RRMS who remain on their initial therapy.

show abstract

“…However, the prevalence of anxiety and its relation to socio-demographic and clinical characteristics of the MS patient population is much less thoroughly investigated than prevalence of depression in the general population and needs much more attention from scientists [19].…”

Section: Discussionmentioning

confidence: 99%

Anxiety and social activities in multiple sclerosis patients

Leonavičius

Adomaitienė

2012

Open Medicine

View full text Add to dashboard Cite

AbstractDespite that the prevalence of depression has been thoroughly analyzed in multiple sclerosis (MS) patients and affects approximately 15%–20% of the MS population, attention paid to social activities concomitant with anxiety is still too sporadic. The aim of this study was to find the prevalence of anxiety and social activities aggraded/aggravated with anxiety in the MS population in Lithuania and to analyze how it correlates with socio-demographic factors, clinical outcomes of MS and depression. Three hundred twelve MS patients took part in this study; anxiety prevalence was pointed in 20.2%. Only 23.4% of the study population was socially active. Our study shows a significant level of anxiety and low level of social activity in people with MS. Anxiety in MS patients was strongly related with younger age, shorter MS duration, prevalence of depression and lower level of social activity. A higher level of social activity was significantly related with older urban MS patients who indicated family status as living together and longer MS duration.

show abstract

The Association of Illness Severity, Self-Reported Cognitive Impairment, and Perceived Illness Management with Depression and Anxiety in a Multiple Sclerosis Clinic Population

Cited by 73 publications

References 53 publications

The Perceived Deficits Questionnaire

The Perceived Deficits Questionnaire

Relationship Between Disease-Modifying Therapy and Depression in Multiple Sclerosis

Anxiety and social activities in multiple sclerosis patients

Contact Info

Product

Resources

About